Table of Contents
1 Cover
7 CHAPTER 1: THE $1000 PILL REFERENCES
8 CHAPTER 2: ENTER THE PAYERS REFERENCES
9 CHAPTER 3: PANDEMIC REFERENCES
10 CHAPTER 4: FEDERAL INVESTMENT IN R&D REFERENCES
11 CHAPTER 5: INSULIN REFERENCES
12 CHAPTER 6: THE COSTLY ALZHEIMER’S DISEASE DRUG REFERENCES
13 CHAPTER 7: GENE THERAPY REFERENCES
14 CHAPTER 8: PROVING THE VALUE OF EXPENSIVE DRUGS REFERENCES
15 CHAPTER 9: GENERIC DRUGS REFERENCES
16 CHAPTER 10: ABOUT THOSE SOARING PHARMA PROFITS REFERENCES
17 CHAPTER 11: SCHEMES TO LOWER DRUG PRICES REFERENCES
19 Index
List of Tables
1 Chapter 3TABLE 3.1 mRNA timeline for Moderna and Pfizer
List of Illustrations
1 Chapter 5Graph 5.1 Lantus cost over time.
2 Chapter 7Figure 7.1 Competition of spinal muscular atrophy drugs.
3 Chapter 10Figure 10.1 Healthcare spending 2003–2018.
Guide
10 Index
11 WILEY END USER LICENSE AGREEMENT
Pages
1 iii
2 iv
3 v
4 ix
5 x
6 xi
7 xii
8 1
9 2
10 3
11 4
12 5